Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study [0.03%]
欧洲EURO-SKI生物标志物研究：慢性髓性白血病患者无需治疗的缓解和分子复发的全面分子特征分析
S Rinaldetti,M Chepeleva,A Hedblom et al.
S Rinaldetti et al.
The European Stop Kinase Inhibitors (EURO-SKI) trial was launched to investigate the discontinuation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML). The molecular mechanisms underlying sustained treatme...
Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity [0.03%]
CBPD-409通过靶向降解CREB结合蛋白/ p300在多发性骨髓瘤中表现出强大的抗肿瘤活性
S Corradini,M Maksimos,F Azab et al.
S Corradini et al.
Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study [0.03%]
同种异体造血细胞移植治疗T细胞/巨噬细胞丰富型大B细胞淋巴瘤：欧洲血液和骨髓移植淋巴瘤工作组研究
Simon Renders,Maud Ngoya,Laurence de Leval et al.
Simon Renders et al.
Frank Cichocki,Martin Felices,Anders W Matson et al.
Frank Cichocki et al.
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia [0.03%]
急性髓系白血病中BRAF突变的预后及治疗意义
Darren Lee,Yazan Abu-Shihab,Kate Plas et al.
Darren Lee et al.
Mutations in the RAS/MAPK signaling pathway are recurrent in acute myeloid leukemia (AML), primarily involving NRAS and KRAS. In contrast, mutations in the gene encoding an effector protein, BRAF, occur at relatively lower frequencies in AM...
Response kinetics as a dynamic prognostic marker in patients with multiple myeloma [0.03%]
复发性多发性骨髓瘤患者中反应动力学的动态预后标志研究
Hee Jeong Cho,Myung-Won Lee,Jae Hoon Lee et al.
Hee Jeong Cho et al.
Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib [0.03%]
直接测量体内BCR::ABL1激酶抑制作用显示艾伏尼布比伊马替尼和尼洛替尼具有更强的活性
Chung Hoow Kok,Naranie Shanmuganathan,Verity A Saunders et al.
Chung Hoow Kok et al.
Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma [0.03%]
系统性抗病毒免疫的丧失和LMP1驱动的抑制性髓样肿瘤生态位在EB病毒阳性弥漫性大B细胞淋巴瘤免疫生物学中的汇聚作用
Éanna Fennell,Soi C Law,Alexander C Dowell et al.
Éanna Fennell et al.
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (EBV⁺DLBCL) is an aggressive lymphoma with poor outcomes and an incompletely understood pathogenesis, frequently attributed to immunosenescence. However, its occurrence across...
Low-normal immunoglobulin suggests monoclonal B-cell lymphocytosis and constitutional CLL susceptibility: a dual-mechanism analysis [0.03%]
低正常的免疫球蛋白提示单克隆B细胞淋巴细胞性和遗传性小淋巴细胞白血病易感：双机制分析
Ramon Cohen,Shay Nemet,Shira Bezalel-Rosenberg et al.
Ramon Cohen et al.
Low-normal serum immunoglobulin (Ig) levels may reflect early immune dysregulation preceding chronic lymphocytic leukemia (CLL), but their prognostic significance years before diagnosis is unclear. We conducted a large retrospective cohort ...
Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report [0.03%]
淋巴结为主型霍奇金淋巴瘤的争议与见解——全球NLPHL工作组会议报告
Jamie E Flerlage,Monica Palese,Suzi Birz et al.
Jamie E Flerlage et al.